Kiromic BioPharma, Inc. (KRBP)
After hours:
| Previous close | 0.3369 |
| Open | 0.3370 |
| Bid | 0.3074 x 800 |
| Ask | 0.3300 x 38500 |
| Day's range | 0.2910 - 0.3370 |
| 52-week range | 0.2910 - 11.0000 |
| Volume | |
| Avg. volume | 360,345 |
| Market cap | 4.739M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
HOUSTON, May 13, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces financial results for the first quarter ended March 31, 2022.
- Business Wire
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022
HOUSTON, May 11, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the Company will submit an amended Investigational New Drug Application (IND) for its first oncology cell therapy candidate Procel™ directly to the FDA in t
- Business Wire
Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation
HOUSTON, April 11, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Company’s most recent corporate presentation. The updated presentation can be accessed on the investor relations sec
